Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Panitumumab|BIOLOGICAL: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)